Vanguard Group Inc. Has $296.19 Million Stock Holdings in Amedisys, Inc. $AMED

Vanguard Group Inc. cut its stake in Amedisys, Inc. (NASDAQ:AMED) by 0.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,197,511 shares of the health services provider’s stock after selling 18,609 shares during the period. Vanguard Group Inc. owned approximately 9.74% of Amedisys worth $296,185,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of AMED. Hexagon Capital Partners LLC raised its holdings in shares of Amedisys by 108.1% during the 1st quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider’s stock worth $29,000 after buying an additional 161 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Amedisys by 56.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider’s stock worth $31,000 after buying an additional 120 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Amedisys by 68.1% during the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock worth $32,000 after buying an additional 141 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Amedisys by 100.0% during the 1st quarter. UMB Bank n.a. now owns 386 shares of the health services provider’s stock worth $36,000 after buying an additional 193 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in shares of Amedisys during the 4th quarter worth $55,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Price Performance

Shares of AMED opened at $101.01 on Monday. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $101.02. The business has a 50-day simple moving average of $98.02 and a two-hundred day simple moving average of $94.76. The company has a quick ratio of 1.36, a current ratio of 1.36 and a debt-to-equity ratio of 0.26. The stock has a market cap of $3.32 billion, a PE ratio of 39.30, a PEG ratio of 1.34 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.15. Amedisys had a return on equity of 12.91% and a net margin of 3.56%. The business had revenue of $621.86 million during the quarter, compared to analysts’ expectations of $614.61 million. During the same quarter in the prior year, the firm earned $0.98 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen cut Amedisys from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 24th.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.